Technological advancements in cancer diagnostics: Improvements and limitations

A Pulumati, A Pulumati, BS Dwarakanath… - Cancer …, 2023 - Wiley Online Library
Background Cancer is characterized by the rampant proliferation, growth, and infiltration of
malignantly transformed cancer cells past their normal boundaries into adjacent tissues. It is …

Recent advances in bioorthogonal click chemistry for enhanced PET and SPECT radiochemistry

X Zhong, J Yan, X Ding, C Su, Y Xu… - Bioconjugate …, 2023 - ACS Publications
Due to their high reaction rate and reliable selectivity, bioorthogonal click reactions have
been extensively investigated in numerous research fields, such as nanotechnology, drug …

Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer

F Shao, Z Pan, Y Long, Z Zhu, K Wang, H Ji… - Journal of …, 2022 - Springer
Background Triple-negative breast cancer (TNBC) is more prone to distant metastasis and
visceral recurrence in comparison to other breast cancer subtypes, and is related to dismal …

[HTML][HTML] Imaging diagnosis and efficacy monitoring by [89Zr] Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies

H He, X Qi, H Fu, J Xu, Q Zheng, L Chen, Y Zhang… - Theranostics, 2024 - ncbi.nlm.nih.gov
Rationale: Although programmed death-ligand 1 (PD-L1) inhibitors have achieved efficacy
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …

Effect of aerobic exercise on cardiotoxic outcomes in women with breast cancer undergoing anthracycline or trastuzumab treatment: a systematic review and meta …

Z Ma, S Yao, Y Shi, N Lu, F Cheng - Supportive Care in Cancer, 2022 - Springer
Purpose We aimed to assess the impact of aerobic exercise (AE) on parameters related to
cardiotoxicity in breast cancer (BC) patients receiving anthracycline or trastuzumab …

Non-conventional and investigational PET radiotracers for breast cancer: a systematic review

M Balma, V Liberini, M Racca, R Laudicella… - Frontiers in …, 2022 - frontiersin.org
Breast cancer is one of the most common malignancies in women, with high morbidity and
mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine …

[HTML][HTML] GRPR-targeting radiotheranostics for breast cancer management

A D'Onofrio, S Engelbrecht, T Läppchen… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Breast Cancer (BC) is the most common cancer worldwide and, despite the advancements
made toward early diagnosis and novel treatments, there is an urgent need to reduce its …

Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients

J Liu, X Guo, L Wen, L Wang, F Liu, G Song… - European Journal of …, 2023 - Springer
Purpose A novel HER2 affibody-based molecular probe,[18F] AlF-RESCA-HER2-BCH, was
developed for reducing renal uptake, evaluated, and compared with [18F] AlF-NOTA-HER2 …

Comparison of three 18F-labeled 2-nitroimidazoles for imaging hypoxia in breast cancer xenografts:[18F] FBNA,[18F] FAZA and [18F] FMISO

SN Dos Santos, M Wuest, HS Jans, J Woodfield… - Nuclear Medicine and …, 2023 - Elsevier
Background Tumour hypoxia is associated with increased metastasis, invasion, poor
therapy response and prognosis. Most PET radiotracers developed and used for clinical …

Radiolabeled methotrexate loaded chitosan nanoparticles as imaging probe for breast cancer: Biodistribution in tumor-bearing mice

M Ekinci, C Koksal-Karayildirim… - Journal of Drug Delivery …, 2023 - Elsevier
There is great interest in developing nanoparticle drug delivery systems for the delivery of
therapeutics or imaging agents for cancer. In this context, a new radiopharmaceutical was …